014950.KQ Samik Pharm.

Healthcare Biotechnology KOSDAQ
7,080 KRW
Close of Oct 31, 2026
3,705 24,974
Market cap
KRW 71.3B
P/E
-
P/B
0.98x
ROE
3.2%
Dividend yield
0.40%
Fundamental score
0.9/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 014950.KQ undervalued?

Graham number

The Graham number of Samik Pharm. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Samik Pharm. fundamental analysis

5 of 22 checks passed

ROE 0/2

Low return on equity (3.2%), below 10%.

ROA 1/1

Return on assets (2.7%) is above the industry median (-10.1%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 0/1

Earnings per share history is shorter than 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 0/1

Last year's EPS growth (-116.7%) is below the industry median (4.8%).

Revenue Growth 0/2

Revenue did not grow over the past 3 years or is not reported.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 0/2

Debt to equity cannot be calculated: debt is not reported or equity is negative.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Debt Coverage 0/1

Debt is not reported.

Interest Coverage 1/1

No interest expense reported.

PE vs Market 0/1

PE is negative or not available.

PE vs Industry 0/1

PE is negative or not available.

PBV 1/1

Price to book (1.0x) is below the industry median (2.4x).

Graham Number 0/1

Graham number needs positive earnings and book value.

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

Dividend yield (0.4%) is in the bottom 25% of dividend payers in the market.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Samik Pharm. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Samik Pharm.

Samik Pharmaceutical Company LTD. develops and manufactures pharmaceuticals. The company offers oral therapeutic pharmaceuticals. It also provides drug compounds, drug delivery systems, drug repositioning, and reinforcement of biopharmaceuticals. The company was founded in 1973 and is based in Seoul, South Korea.

Full company profile